French pharmaceutical company Ipsen SA (IPSEY) and late-stage biopharmaceutical company GENFIT SA (GNFT) announced Friday positive topline data from the pivotal ELATIVE Phase III trial of elafibranor in patients with primary biliary cholangitis or PBC, a rare cholestatic liver disease.